Aidaptus auto-injector wins Red Dot award for product design

Owen Mumford‘s Aidaptus auto-injector, which lets a wide range of under-the-skin medications to be administered, has won a Red Dot Award in the Product Design 2023 category.

Launched in 2021, Aidaptus is a disposable auto-injector whose design fits multiple-sized prefilled glass syringes without changing parts. This could provide companies with a single solution for delivering all kinds of drug formulations, enabling people with multiple sclerosis (MS) and other diseases self-administer their medications with fewer hurdles.

“Our Aidaptus auto-injector platform has been designed to reduce complexity and provide a flexible solution for pharmaceutical and biotechnology companies who are developing a variety of drug formulations for subcutaneous delivery,” Michael Earl, director of pharmaceutical services at Owen Mumford, said in a company press release.

In MS, the device could also help administer a number of subcutaneous (under-the-skin) disease-modifying therapies approved for relapsing types of the disease.

These include interferon based medications, such as Betaseron, Extavia, Plegridy, and Rebif, as well as glatiramer acetate (sold as Copaxone and others), and Kesimpta (ofatumumab).

Recommended Reading

April 4, 2023 News by Margarida Maia, PhD

Sensoready Pen easier to use for MS therapy than other devices: Survey

The compact design of the device provides a simple two-step injection process, letting patients administer their subcutaneous medication at home and helping reduce the burden on healthcare providers and services.

It accommodates both 1 mL and 2.25 mL prefilled syringes in the same device and has a patented self-adjusting plunger that automatically adapts to different fill volumes in each syringe, with no need to change parts. The choice of delivery springs accommodates higher-viscosity formulations, such as biologics, to be administered.

Aidaptus “tackles the challenges of changes to drug formulation or injected volume and can therefore help reduce risk during drug development and lifecycle management,” Earl said.

The injector will be manufactured in state-of-the-art factories in Malaysia and in Owen Mumford’s new production facility in the U.K., which should be finished later this year. Owen Mumford is also collaborating with Stevanato Group for the device’s molding and assembly, which will ensure continuous availability by having two suppliers.

The Red Dot Award is one of the biggest design competitions in the world where more than 40 international expert judges award excellent designs across a variety of products each year. The “Red Dot” is one of the most desired seals of quality for good design.

“Red Dot is one of the most prestigious design competitions that is highly competitive, and we are honored to be globally recognized with distinction in the Product Design 2023 category,” said Jarl Severn, CEO at Owen Mumford. “We have previously enjoyed this accolade for our Unifine Pentips Plus pen needle and today’s news further underscores our ongoing pursuit and commitment to excellence in design.”